Patent ID: 11865088
Assignee: CLEXIO BIOSCIENCES LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating major depressive disorder (MDD) in a
human patient in need thereof consisting essentially of orally administering to said patient an oral dosage form of between 20 mg and 40 mg of esketamine over a treatment regimen of at least 28 days;
and optionally administering to said patient a second medication that is an antidepressant, an antimanic agent, or an anxiolytic drug that does not alter the metabolism of the esketamine in the patient,
wherein the ratio of S-norketamine Cmax to esketamine Cmax after the co-administration of the esketamine and the second medication is at least 6.